Literature DB >> 20560983

Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells.

S M Stenman1, K Lindfors, J I Venäläinen, A Hautala, P T Männistö, J A Garcia-Horsman, A Kaukovirta-Norja, S Auriola, T Mauriala, M Mäki, K Kaukinen.   

Abstract

Currently the only treatment for coeliac disease is a lifelong gluten-free diet excluding food products containing wheat, rye and barley. There is, however, only scarce evidence as to harmful effects of rye in coeliac disease. To confirm the assumption that rye should be excluded from the coeliac patient's diet, we now sought to establish whether rye secalin activates toxic reactions in vitro in intestinal epithelial cell models as extensively as wheat gliadin. Further, we investigated the efficacy of germinating cereal enzymes from oat, wheat and barley to hydrolyse secalin into short fragments and whether secalin-induced harmful effects can be reduced by such pretreatment. In the current study, secalin elicited toxic reactions in intestinal Caco-2 epithelial cells similarly to gliadin: it induced epithelial cell layer permeability, tight junctional protein occludin and ZO-1 distortion and actin reorganization. In high-performance liquid chromatography and mass spectroscopy (HPLC-MS), germinating barley enzymes provided the most efficient degradation of secalin and gliadin peptides and was thus selected for further in vitro analysis. After germinating barley enzyme pretreatment, all toxic reactions induced by secalin were ameliorated. We conclude that germinating enzymes from barley are particularly efficient in the degradation of rye secalin. In future, these enzymes might be utilized as a novel medical treatment for coeliac disease or in food processing in order to develop high-quality coeliac-safe food products.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20560983      PMCID: PMC2909406          DOI: 10.1111/j.1365-2249.2010.04119.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease.

Authors:  Luigi Maiuri; Carolina Ciacci; Ida Ricciardelli; Loredana Vacca; Valeria Raia; Salvatore Auricchio; Jean Picard; Mohamed Osman; Sonia Quaratino; Marco Londei
Journal:  Lancet       Date:  2003-07-05       Impact factor: 79.321

Review 2.  Future therapeutic options for celiac disease.

Authors:  Ludvig M Sollid; Chaitan Khosla
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-03

3.  Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3.

Authors:  Karen M Lammers; Ruliang Lu; Julie Brownley; Bao Lu; Craig Gerard; Karen Thomas; Prasad Rallabhandi; Terez Shea-Donohue; Amir Tamiz; Sefik Alkan; Sarah Netzel-Arnett; Toni Antalis; Stefanie N Vogel; Alessio Fasano
Journal:  Gastroenterology       Date:  2008-03-21       Impact factor: 22.682

4.  Intestinal digestive resistance of immunodominant gliadin peptides.

Authors:  Felix Hausch; Lu Shan; Nilda A Santiago; Gary M Gray; Chaitan Khosla
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-10       Impact factor: 4.052

5.  Enzymatic detoxification of gluten by germinating wheat proteases: implications for new treatment of celiac disease.

Authors:  Satumarja M Stenman; Jarkko I Venäläinen; Katri Lindfors; Seppo Auriola; Timo Mauriala; Anu Kaukovirta-Norja; Anna Jantunen; Kaija Laurila; Shuo-Wang Qiao; Ludvig M Sollid; Pekka T Männisto; Katri Kaukinen; Markku Mäki
Journal:  Ann Med       Date:  2009       Impact factor: 4.709

6.  Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture.

Authors:  K Lindfors; T Blomqvist; K Juuti-Uusitalo; S Stenman; J Venäläinen; M Mäki; K Kaukinen
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

7.  Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes.

Authors:  Seiji Yokoyama; Nobumasa Watanabe; Noriko Sato; Pin-Yu Perera; Lyvouch Filkoski; Toshiyuki Tanaka; Masayuki Miyasaka; Thomas A Waldmann; Takachika Hiroi; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-01       Impact factor: 11.205

8.  Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2.

Authors:  Amit Tripathi; Karen M Lammers; Simeon Goldblum; Terez Shea-Donohue; Sarah Netzel-Arnett; Marguerite S Buzza; Toni M Antalis; Stefanie N Vogel; Aiping Zhao; Shiqi Yang; Marie-Claire Arrietta; Jon B Meddings; Alessio Fasano
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-15       Impact factor: 11.205

9.  Oats do not induce systemic or mucosal autoantibody response in children with coeliac disease.

Authors:  Outi Koskinen; Mikko Villanen; Ilma Korponay-Szabo; Katri Lindfors; Markku Mäki; Katri Kaukinen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-05       Impact factor: 2.839

10.  A food-grade enzyme preparation with modest gluten detoxification properties.

Authors:  Jennifer Ehren; Belen Morón; Edith Martin; Michael T Bethune; Gary M Gray; Chaitan Khosla
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

View more
  5 in total

Review 1.  Non-dietary forms of treatment for adult celiac disease.

Authors:  Hugh James Freeman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

Review 2.  Review article: coeliac disease, new approaches to therapy.

Authors:  S Rashtak; J A Murray
Journal:  Aliment Pharmacol Ther       Date:  2012-02-13       Impact factor: 8.171

Review 3.  The gluten-free diet: testing alternative cereals tolerated by celiac patients.

Authors:  Isabel Comino; María de Lourdes Moreno; Ana Real; Alfonso Rodríguez-Herrera; Francisco Barro; Carolina Sousa
Journal:  Nutrients       Date:  2013-10-23       Impact factor: 5.717

4.  Plant Proteases: From Key Enzymes in Germination to Allies for Fighting Human Gluten-Related Disorders.

Authors:  Manuel Martinez; Sara Gómez-Cabellos; María José Giménez; Francisco Barro; Isabel Diaz; Mercedes Diaz-Mendoza
Journal:  Front Plant Sci       Date:  2019-05-29       Impact factor: 5.753

5.  Gamma-gliadin specific celiac disease antibodies recognize p31-43 and p57-68 alpha gliadin peptides in deamidation related manner as a result of cross-reaction.

Authors:  Ádám Diós; Rita Elek; Ildikó Szabó; Szilvia Horváth; Judit Gyimesi; Róbert Király; Katharina Werkstetter; Sibylle Koletzko; László Fésüs; Ilma R Korponay-Szabó
Journal:  Amino Acids       Date:  2021-05-31       Impact factor: 3.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.